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Background: In the ISAR-REACT 4 clinical trial in 1721 randomized patients
undergoing percutaneous coronary angioplasty for non-ST elevation myocardial infarc-
tion, treatment with abciximab and heparin demonstrated an increased risk of bleeding in
comparison to bivalirudin. However the results were not analyzed with respect to the age
of the patients and it was not clear if this excess bleeding risk occurred in any particular
sub-group.
Methods: In this study, the patients from the ISAR REACT study were organized into
four quartile groups according to age, and the outcomes analyzed with respect to treatment
with abciximab and heparin or bivalirudin. The primary endpoint was the composite of
death, large myocardial infarction, urgent target vessel revascularization or major bleeding
within 30 days. The secondary endpoints were death, myocardial infarction or target
vessel revascularization (efficacy endpoint) and major bleeding (safety endpoint) at 30
days.
Results: A total of 1721 patients entered the study. The primary endpoint occurred in
11.8% vs. 11.6% in Q1, 10.2% vs. 9.8% in Q2, 10.7% vs. 10.3% in Q3 and 11.0% vs.
12.4% in Q4 in patients treated with abciximab and heparin or bivalirudin respectively.
There was no overall interaction between age and occurrence of the primary endpoint
(PINTERACTION0.81). There were no differences within the age quartile groups and
no interaction between age and clinical outcome for the secondary efficacy endpoint
(PINTERACTION0.84) or for the primary safety endpoint (PINTERACTION0.59)
Conclusions: In patients undergoing treatment for non-ST elevation myocardial infarc-
tion and stratified by age, there were no differences in clinical outcome, safety or efficacy
between those receiving abciximab and those receiving bivalirudin. This finding was
consistent across a variety of key risk sub-groups.
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Background: Randomized trials and registries have shown that everolimus-eluting stent
(EES) performs better than first generation drug-eluting stent (DES). Prasugrel as
compared to clopidogrel in acute coronary syndromes treated invasively is associated with
improved clinical outcome and decreased risk of stent thrombosis. No data exist about
prasugrel as compared to clopidogrel il patients with unprotected left main disease
(ULMD) treated with EES. The aim of the study was to compare clinical outcome in
patients receiving Clopidogrel or Prasugrel who underwent ULMD-PCI with EES.
Methods: From the prospective Florence LM-PCI registry, consecutive patients receiv-
ing EES were included in the analysis. Antiplatelet treatment included clopidogrel until
March 2010, while prasugrel was routinely used from April 2010. The end points of the
study were cardiac mortality and stent thrombosis at 1 year of follow-up. Definite,
probable and possible stent thromboses were defined according to the Academic Research
Consortium criteria.
Results: From January 2004 to 2011, 192 patients underwent EES implantation for
ULMD. Out of these 94 pts received clopidogrel and 98 received prasugrel. Patients on
prasugrel therapy had a worse baseline risk profile than patients on clopidogrel, but these
differences did not reach statistical significance: mean age 70 10 vs. 71 11 yrs, male
78% vs. 75%, diabetes 28% vs. 21%, acute myocardial infarction 15% vs. 8%, left
ventricular ejection fraction 0.40 40% vs. 32%, renal insufficiency (creatinine  1.5
mg/dL) 15% vs. 8%, 3-vessel disease vs 35% vs 30%, EuroSCORE 13 31% vs. 21%.
Procedural characteristics were similar in prasugrel group and clopidogrel group: LM
stenting of both branches 30% vs. 28%, respectively, mean stent length (mm) 24 12 vs.
21 10, IVUS guidance 58% vs 56%. One-year clinical outcome was significantly better
in the prasugrel group as compared to clopidogrel group: cardiac mortality rate 2.0% and
8.5%, respectively (p0.044), stent thrombosis rate 0 vs. 4.3% (p0.039).
Conclusions: As compared to clopidogrel, prasugrel improves clinical outcome in all
comers patients with ULMD receiving EES.
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Background: In HORIZONS-AMI, bivalirudin (Biv) compared to heparin 	 a GPIIb/
IIIa inhibitor (H	GPI) in pts with STEMI undergoing primary PCI resulted in reduced
rates of major bleeding and cardiac mortality. Whether the reduction in mortality with Biv
can be fully ascribed to reduced bleeding is unknown.
Methods: We examined the rates of cardiac mortality among pts randomized to Biv vs
H	GPI in those with and w/o non-CABG major bleeding during 3 yr follow-up in a time-
and covariate-adjusted multivariable model.
Results: The 3 yr rates of non-CABG major bleeding (6.7% vs 10.3%, P0.0007) and
cardiac mortality (2.8% vs 4.9%, P0.001) were lower in pts randomized to Biv vs
H	GPI. Among 306 pts with major bleeding, cardiac mortality at 3 yrs occurred in 7/121
(5.8%) and 27/185 (14.6%) pts assigned to Biv vs H	GPI, respectively, HR[95%CI]
0.39 [0.17-0.89], P0.02. Among 3296 pts w/o bleeding, 3 yr cardiac mortality occurred
in 43/1679 (2.6%) and 61/1617 (3.8%) pts assigned to Biv vs H	GPI, respectively,
HR[95%CI] 0.67 [0.46-1.00], P0.046. Thus 20 fewer deaths occurred in Biv treated
patients with a major bleed compared to 18 fewer deaths in Biv treated patients w/o a
major bleed. In the fully adjusted model Biv treatment was associated with reduced
cardiac mortality both in pts with (HR[95%CI] 0.32 [0.14,0.78], P0.01) and w/o
(HR[95%CI] 0.65 [0.44,0.97], P0.03) major bleeding. Among pts w/o bleeding fewer
pts treated with Biv developed new thrombocytopenia (147/1625 (9.0%) vs 180/1546
(11.6%), p0.02). In pts w/o bleeding the adjusted HR [95%CI] for 3 yr cardiac mortality
with Biv vs H	GPI was 0.22 [0.06,0.84], p0.01 vs 0.78 [0.49,1.24], p0.29 in those
with vs. w/o acquired thrombocytopenia
Conclusions: In pts with STEMI undergoing primary PCI, procedural anticoagulation
with Biv rather than H	GPI is associated with reduced cardiac mortality among pts with
as well as those w/o major bleeding, a benefit which may be attributed to prevention of
thrombocytopenia.
TCT-53
Assessment of 30-Day Rehospitalization For Acute Myocardial Infarction In
Patients With Acute Coronary Syndrome Who Received Percutaneous
Coronary Intervention: A Comparative Effectiveness Study Of Clopidogrel
And Prasugrel
Jay Bae1, Douglas Faries1, Frank Ernst2, Craig Lipkin2, Zhenxiang Zhao1,
Chad Moretz2
1Eli Lilly and Company, Indianapolis, IN, 2Premier Research Services,
Charlotte, NC
Background: A 30-day rehospitalization rate for acute myocardial infarction (AMI)
following hospital discharge among patients with acute coronary syndrome (ACS) who
have received percutaneous coronary intervention (PCI) has been adopted as a hospital
quality and performance measure. This study sought to compare 30- and 90-day
AMI-related rehospitalization rates between ACS-PCI patients receiving clopidogrel
versus those receiving prasugrel.
Methods: The study endpoint was pre-specified, and analysis was done under blinding.
Using a large geographically diverse US database maintained by PREMIER, the study
analyzed AMI-related rehospitalizations among ACS-PCI patients receiving either clopi-
dogrel or prasugrel between July 2009 and June 2011. Analysis included patients treated
with prasugrel who were on-label and clopidogrel-treated patients who would have been
eligible for prasugrel treatment per the label. Treatment differences in rehospitalization
rate at 30 and 90 days were analyzed. Unadjusted comparisons used chi-square tests.
Multivariate logistic regression analyses adjusted for baseline patient differences using
propensity score stratification.
Results: Data were available for 83,576 patients, of which 74,163 received clopidogrel
and 9,403 received prasugrel. For clopidogrel and prasugrel, respectively, the observed
AMI-related rehospitalization rates were 4.74% and 3.85% at 30 days (P0.0001) and
6.27% and 5.13% at 90 days (P0.0001). Prasugrel was associated with approximately
10% lower odds of AMI-related rehospitalization (Odds ratio0.892 at 30 days [95% CI:
0.798-0.998]; Odds ratio0.901 at 90 days [95% CI: 0.817-0.994]).
Conclusions: Compared to clopidogrel-treated patients, prasugrel-treated patients expe-
rienced fewer rehospitalizations for AMI at 30 days and 90 days following ACS-PCI
discharge. Similar results were obtained after adjusting for patient demographics and
clinical characteristics. The potential for unmeasured confounder bias is a limitation in this
real-world observational research.
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